Curated News
By: NewsRamp Editorial Staff
September 05, 2024
Mainz Biomed N.V. and Liquid Biosciences Partner to Fight Pancreatic Cancer
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Mainz's collaboration with Liquid Biosciences gives an advantage in detecting deadly cancers earlier, potentially leading to improved survival rates.
- Mainz Biomed is developing PancAlert, a screening test combining genetic and microbiome biomarkers to detect pancreatic cancer, aiming to complete the analysis by the fourth quarter of 2024.
- Mainz's collaboration with Liquid Biosciences aims to bring the power of AI to the critical problem of early-stage pancreatic cancer detection, potentially improving survival rates.
- Research has shown that the microbiome plays a big role in how tumors develop and progress, potentially impacting the immune system and the effectiveness of cancer drugs.
Impact - Why it Matters
This collaboration between Mainz Biomed and Liquid Biosciences is crucial in the battle against pancreatic cancer, one of the most lethal forms of the disease. The potential addition of pancreatic cancer detection to Mainz's screening test could lead to earlier diagnosis and better treatment outcomes for patients.
Summary
Mainz Biomed N.V. (NASDAQ: MYNZ) has partnered with Liquid Biosciences to potentially add pancreatic cancer detection to its ColoAlert® screening test. The collaboration aims to combine genetic and microbiome biomarkers for early cancer detection, with promising initial results. Pancreatic cancer is a deadly and growing disease, with Mainz's collaboration representing a significant step in the fight against this lethal form of cancer.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Mainz Biomed N.V. and Liquid Biosciences Partner to Fight Pancreatic Cancer
